Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Tear deficiency medications (OR: 10.54, 95% CI: 3.78 to 29.39), bisphosphonates (OR: 6.83, 95% CI: 3.45 to 13.52), vitamin D with calcium (OR: 6.11, 95% CI: 3.70 to 10.09), non-opioid analgesics (OR: 2.54, 95% CI: 1.85 to 3.50), topical non-steroidal anti-inflammatory drugs (NSAIDs) (OR: 2.02, 95% CI: 1.05 to 3.88), selective serotonin reuptake inhibitors (SSRIs) (OR: 2.86, 95% CI: 1.38 to 5.94), thiazides and related diuretics (OR: 2.54, 95% CI: 1.29 to 4.98), tricyclic and related antidepressants (OR: 2.34, 95% CI: 1.01 to 5.44) and emollients (OR: 1.78, 95% CI: 1.12 to 2.82) showed a significant difference in favour of women.
Source: Gender differences in medication prescription. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Characterising polypharmacy in the very old: Findings from the Newcastle 85+ Study
Study design awaiting verification · PLoS ONE · 2021
Original publication title
Characterising polypharmacy in the very old: Findings from the Newcastle 85+ Study
© 2021 Davies et al
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Polypharmacy is potentially harmful and under-researched amongst the fastest growing subpopulation, the very old (aged ≥85). We aimed to characterise polypharmacy using data from the Newcastle 85+ Study: a prospective cohort of people born in 1921 who turned 85 in 2006 (n = 845).
Source: BackgroundAbstract: What methods does the paper describe?
The prevalence of polypharmacy at baseline (mean age 85.5) was examined using cut-points of 0, 1, 2 to 4, 5 to 9 and ≥10 medicines: so-called ‘no polypharmacy’, ‘monotherapy’, ‘minor polypharmacy’, ‘polypharmacy’ and ‘hyperpolypharmacy.’ Cross-tabulations and upset plots identified the most frequently prescribed medicines and medication combinations within these categories. Mixed-effects models assessed whether gender and socioeconomic position were associated with prescribing changes over time (mean age 85.5 to 90.5). Participant characteristics were examined through descriptive statistics.
Source: MethodsAbstract: Results
Complex multimorbidity (44.4%, 344/775) was widespread but hyperpolypharmacy was not (16.0%, 135/845). The median medication count was six (interquartile range 4 to 8). Preventative medicines were common to all polypharmacy categories, and prescribing regimens were diverse. Nitrates and oral anticoagulants were more frequently prescribed for men, whereas bisphosphonates, non-opioid analgesics and antidepressants were more common in women. Cardiovascular medicines, including loop diuretics, tended to be more frequently prescribed for socioeconomically disadvantaged people (<25th centile Index of Multiple Deprivation (IMD)), despite no difference in the prevalence of cardiovascular disease (p = 0.56) and diabetes (p = 0.92) by IMD.
Source: ResultsAbstract: Conclusion
Considering their complex medical conditions, prescribing is relatively conservative amongst 85-year-olds living in North East England. Prescribing shows significant gender and selected socioeconomic differences. More support for managing preventative medicines, of uncertain benefit, might be helpful in this population.
Source: ConclusionAuthors’ abstract
Background
Polypharmacy is potentially harmful and under-researched amongst the fastest growing subpopulation, the very old (aged ≥85). We aimed to characterise polypharmacy using data from the Newcastle 85+ Study: a prospective cohort of people born in 1921 who turned 85 in 2006 (n = 845).
Methods
The prevalence of polypharmacy at baseline (mean age 85.5) was examined using cut-points of 0, 1, 2 to 4, 5 to 9 and ≥10 medicines: so-called ‘no polypharmacy’, ‘monotherapy’, ‘minor polypharmacy’, ‘polypharmacy’ and ‘hyperpolypharmacy.’ Cross-tabulations and upset plots identified the most frequently prescribed medicines and medication combinations within these categories. Mixed-effects models assessed whether gender and socioeconomic position were associated with prescribing changes over time (mean age 85.5 to 90.5). Participant characteristics were examined through descriptive statistics.
Results
Complex multimorbidity (44.4%, 344/775) was widespread but hyperpolypharmacy was not (16.0%, 135/845). The median medication count was six (interquartile range 4 to 8). Preventative medicines were common to all polypharmacy categories, and prescribing regimens were diverse. Nitrates and oral anticoagulants were more frequently prescribed for men, whereas bisphosphonates, non-opioid analgesics and antidepressants were more common in women. Cardiovascular medicines, including loop diuretics, tended to be more frequently prescribed for socioeconomically disadvantaged people (<25th centile Index of Multiple Deprivation (IMD)), despite no difference in the prevalence of cardiovascular disease (p = 0.56) and diabetes (p = 0.92) by IMD.
Conclusion
Considering their complex medical conditions, prescribing is relatively conservative amongst 85-year-olds living in North East England. Prescribing shows significant gender and selected socioeconomic differences. More support for managing preventative medicines, of uncertain benefit, might be helpful in this population.
Publication and source details
Original title: Characterising polypharmacy in the very old: Findings from the Newcastle 85+ Study
Laurie E. Davies; Andrew Kingston; Adam Todd; Barbara Hanratty
PLoS ONE · 2021
Competing Interests: The authors have declared that no competing interests exist.
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T13:35:09.096091+00:00
DOI: 10.1371/journal.pone.0245648 · PMC7815158